Yifan Biopharma has completed a multi-million yuan angel round financing
Recently, Yifan Biopharma announced that it has completed a multi-million yuan angel round financing, with exclusive investment from Shicui Capital. The funds from this round of financing will be mainly used to enhance the company’s innovative peptide biosynthesis technology platform and new product research and development, expand the production capacity of existing products, and promote the application and promotion of advantageous technologies and products domestically and internationally.
Regarding Peptides
Looking globally, the life science industry is showing unprecedented vitality, demonstrating enormous potential in addressing the health, environmental, and resource challenges facing human development.
With the gradual deepening of the division of labor in the pharmaceutical manufacturing industry chain, the domestic CDMO industry has become relatively mature, with the market already in a “red ocean.” In addition to the high concentration of traditional tracks such as small molecules and antibodies, many emerging tracks have also become hot in recent years, entering the global investors’ field of vision.
One of the hot areas in global new drug development, the once overlooked, niche, high-profit peptide track is gradually becoming the next focus track in the CDMO industry that cannot be ignored. Over the past decade, the peptide track has seen the emergence of several “blockbuster” drugs, with GLP-1 agonists primarily used for type II diabetes and obesity treatment standing out. Currently, the hottest “internet celebrity drugs” on the market – Semaglutide, dulaglutide, Liraglutide, among others – are representative GLP-1 agonists, with global sales exceeding $16 billion in 2021.
“Yifan Biopharma was established in 2024, with a core team composed of technical experts in pharmaceutical engineering, fermentation engineering, protein engineering, and other related fields. Leveraging rich practical experience in the field of biomanufacturing, we provide industry partners with innovative and highly attractive solutions for the biosynthesis of peptide drugs. Yifan Biopharma’s unique innovative biosynthesis strategy has been successfully validated on various short peptides and complex cyclic peptides, offering production capacity and cost advantages beyond traditional biological and chemical synthesis methods. This has led to development collaboration orders from numerous well-known pharmaceutical companies and CDMO enterprises. Yifan Biopharma is committed to helping partners stay ahead in the discovery and production process of peptide drugs through innovative biosynthesis technology.
